Dr. Curt LaBelle serves as the Managing Partner and President of the Global Health Investment Fund (GHIF). See sector focus and contact routes.
Dr. Curt LaBelle serves as the Managing Partner and President of the Global Health Investment Fund (GHIF), a $108 million social impact venture fund he joined in 2015 after previously working as a Managing Director at Tull Health Investors. He exclusively invests in companies creating innovative products suitable for low-resource environments, targeting drugs, vaccines, and diagnostics for diseases that disproportionately burden low- and middle-income countries. GHIF’s portfolio includes notable companies such as those developing treatments for cholera, river blindness, and diagnostic tests for tuberculosis, HIV, malaria, dengue, preeclampsia, and gestational diabetes. While specific check sizes are not publicly detailed, the fund emphasizes an investor guarantee mechanism that provides downside protection, ensuring investors recover at least 60% of capital even in worst-case scenarios. LaBelle has held board or access roles at multiple healthcare firms including KAI Pharmaceuticals, Sirion Therapeutics, and Eyenovia, many of which were later acquired. His distinctive point of view centers on the dual focus of achieving measurable health improvements along
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in New York.
Investors like Curt LaBelle · Full investor directory · Investor access · Company funding database